Anal cancer

The European Commission ( EC ) has approved Bavencio ( Avelumab ) as monotherapy for the first-line maintenance treatment of...


The co-primary endpoint results from a recently completed post-marketing required safety study, ORAL Surveillance were presented. The primary objective of...


The European Commission has approved Keytruda ( Pembrolizumab ), an anti-PD-1 therapy, as a monotherapy for the first-line treatment of...


Results from the phase 2 cohort of the CodeBreaK 100 clinical study evaluating investigational Sotorasib ( AMG 510 ) in...


The results from the final analysis of the phase 3 TITAN study, which has demonstrated the continued statistically significant benefit...


Results from an exploratory analysis of the ADAURA phase III trial have shown Osimertinib ( Tagrisso ) has extended disease-free...


The FDA ( U.S. Food and Drug Administration ) has approved the PD-1 inhibitor Libtayo ( Cemiplimab-rwlc; Cemiplimab ) for...


New data from the phase 1/2 trial of Mobocertinib orally administered in previously treated patients with epidermal growth factor receptor...


The FDA ( U.S. Food and Drug Administration ) has approved supplemental New Drug Application ( sNDA ) for Lorbrena...


Results from CLASSICAL-Lung clinical trial were published in Clinical Cancer Research, a publication of the American Association for Cancer Research...



Tagrisso ( Osimertinib ), an irreversible epidermal growth factor receptor tyrosine kinase inhibitor ( EGFR TKI ), has been approved...


In CheckMate 577, Nivolumab ( Opdivo ) has demonstrated a significant and clinically meaningful improvement in disease-free survival ( DFS;...


Dalpiciclib, a novel CDK4/6 inhibitor, as monotherapy has demonstrated tolerability and preliminary antitumor activity in pretreated HR+/HER2− advanced breast cancer...


The European Commission ( EC ) has granted Conditional Marketing Authorization for Abecma ( Idecabtagene vicleucel; Ide-cel ), a first-in-class...


The U.S. Food and Drug Administration ( FDA ) ha approved Opdivo ( Nivolumab ) 240 mg every two weeks...


There has been an only indirect comparison between Pembrolizumab ( Keytruda ) and Pembrolizumab plus chemotherapy in patients with non-small...


The phase III SPARTAN study evaluated Apalutamide ( Erleada ) vs Placebo in patients with non-metastatic castration-resistant prostate cancer (...


MET exon 14 skipping mutations ( METex14 ) are seen in 3-4% of patients with non-small cell lung cancer (...


Ibrutinib ( Imbruvica ), a once-daily Bruton’s tyrosine kinase ( BTK ) inhibitor approved for various B-cell malignancies, also inhibits...